ArticlePLoS neglected tropical diseases2025
Successful control of Triatoma dimidiata with residual application of a microencapsulated formulation of pirimiphos-methyl (Actellic 300CS) in southeast Mexico.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First Detection of the L1014F kdr Mutation in Triatoma dimidiata, a Vector of Chagas Disease in Mexico.Neotropical entomology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundTriatoma dimidiata, the main vector of Trypanosoma cruzi throughout South Mexico and Central America, infest domiciles and peridomestic ecotopes of rural and semi-rural communities. This study reports the effect of the residual application of the organophosphate pirimiphos-methyl in a microencapsulated formulation (Actellic 300CS) for the control of intradomiciliary and peridomestic T. dimidiata in the community of Tekik de Regil (hereafter Tekik) in Yucatan, Southeast Mexico.
methodsFrom March to October 2022, a two-arm, unblinded entomological trial was performed in Tekik. Timed Manual Collections (TMC) characterized house and peridomicile infestation by T. dimidiata prior (baseline) and after the residual spraying (RS) (post-intervention) of a microencapsulated formulation. A total of 120 premises were surveyed (60 positive and 60 negative for T. dimidiata), randomly allocated 1:1 to treatment (RS with Actellic 300CS) and control (no RS) arms. Monthly post-spraying entomological surveys (May-October) with TMC were carried out in a random sample of ten houses from each arm. We analyzed the association between the treatment and post-intervention infestations using chi-square contingency tables. The estimated efficacy of the intervention with the 95% Confidence Intervals (CI) was calculated with the efficacy formula, using the Odds Ratio (OD) calculated from a binomial Generalized Linear Mixed Model (GLMM) from the positive premises in the baseline survey and post-intervention, using time as a random effect.
resultsDomestic infestations post-intervention were only detected in the control group (2/60 houses, 3.3%). Cumulative peridomestic infestation was significantly higher in the control arm (31.7%; 19/60) compared to the treatment arm (11.7%; 7/60) (X2 = 0.007, p < 0.01). The cumulative 6-month estimated efficacy of the intervention (% reduction in treatment versus control arm) was 65% (95% CI: 14%-79%).
conclusionsA single application of Actellic 300CS reduced T. dimidiata infestations by more than 60% for up to 6 months and provides evidence of an alternative formulation suitable for triatomine control in Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.